Evidence map›Paper›PMID 31956893›Full record

ArticleThe Journal of infectious diseases2020

Frailty Is Associated With Mortality and Incident Comorbidity Among Middle-Aged Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Participants.

Eveline Verheij, Gregory D Kirk, Ferdinand W Wit, Rosan A van Zoest, Sebastiaan O Verboeket, Bregtje A Lemkes, Maarten F Schim van der Loeff, Peter Reiss, AGEhIV Cohort

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01466582 (Comorbidity and Aging With HIV, the agehIV Cohort Study), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01466582 active not recruitingnot on this map

Comorbidity and Aging With HIV, the agehIV Cohort Study

TypeobservationalSponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Ran2010 to 2040Enrolled1,148ConditionsHIV-1-infection, Comorbidity, Ageing
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Eveline VerheijAmsterdam University Medical Centers, University of Amsterdam, Department of Global Health and Division of Infectious Diseases, Amsterdam Infection and Immunity Institute and Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
Gregory D KirkDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Ferdinand W WitAmsterdam University Medical Centers, University of Amsterdam, Department of Global Health and Division of Infectious Diseases, Amsterdam Infection and Immunity Institute and Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
Rosan A van ZoestAmsterdam University Medical Centers, University of Amsterdam, Department of Global Health and Division of Infectious Diseases, Amsterdam Infection and Immunity Institute and Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
Sebastiaan O VerboeketAmsterdam University Medical Centers, University of Amsterdam, Department of Global Health and Division of Infectious Diseases, Amsterdam Infection and Immunity Institute and Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
Bregtje A LemkesAmsterdam University Medical Centers, University of Amsterdam, Department of Global Health and Division of Infectious Diseases, Amsterdam Infection and Immunity Institute and Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
Maarten F Schim van der LoeffPublic Health Service of Amsterdam, Department of Infectious Diseases, Amsterdam, The Netherlands.
Peter ReissAmsterdam University Medical Centers, University of Amsterdam, Department of Global Health and Division of Infectious Diseases, Amsterdam Infection and Immunity Institute and Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
AGEhIV Cohort
Amsterdam Institute for Global Health and Development · NLStichting HIV Monitoring · NLAmsterdam University Medical Centers · NLGGD Amsterdam · NLJohns Hopkins University · US

Funding

Patient-Oriented Research and Mentorship in HIV and Non-Communicable DiseasesK24AI118591 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KIRK, GREGORY D · 2015 to 2019
$766k
NIAID NIH HHS K24 AI118591
6 · The paper itself

Abstract

backgroundFrailty is associated with mortality and morbidity in the general geriatric population, but less is known about its impact among the aging but generally younger population with human immunodeficiency virus (HIV).

methodsThe impact of frailty on all-cause mortality during 6 years of follow-up and incident comorbidity during 4 years of follow-up was assessed among 598 HIV-positive and 550 comparable HIV-negative participants aged ≥ 45 years of the AGEhIV Cohort Study. Frailty encompasses 5 domains; weight loss, low physical activity, exhaustion, decreased grip strength, and slow gait speed. Presence of ≥ 3 denotes frailty, 1-2 prefrailty, and 0 robust. Multivariable Cox and logistic regression models were used to assess the independent relationships of frailty with both outcomes, adjusting for HIV infection and traditional risk factors.

resultsAt baseline, 7.5% (n = 86) of participants were frail. During follow-up, 38 participants died. Mortality rate was significantly higher among frail participants: 25.7/1000 person-years of follow-up (PYFU) (95% confidence interval [CI], 14.2-46.4) compared with prefrail (7.2/1000 PYFU [95% CI, 4.7-11.2]) and robust (2.3/1000 PYFU [95% CI, 1.1-4.9]). In fully adjusted analyses, frailty remained strongly associated with death (hazard ratio, 4.6 [95% CI, 1.7-12.5]) and incident comorbidity (odds ratio, 1.9 [95% CI, 1.1-3.1]). No interactions were observed between frailty and HIV status in all analyses.

conclusionsFrailty is a strong predictor of both mortality and incident comorbidity independent from other risk factors. CLINICAL TRIALS REGISTRATION: NCT01466582.

Indexed as

AgedComorbidityFemaleFrailtyHIV InfectionsHIV SeropositivityHumansIncidenceMaleMiddle AgedOdds RatioPublic Health SurveillanceRisk FactorsSymptom AssessmentcomorbiditiesfrailtyHIVinflammationmortality

Identifiers

PMID31956893
PMCPMC7430168
OpenAlexW3002459080

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.